Technical Analysis for SUPN - Supernus Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade F 33.1 -0.45% -0.15
SUPN closed down 0.45 percent on Monday, May 20, 2019, on 54 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Down
See historical SUPN trend table...

Date Alert Name Type % Chg
Narrow Range Bar Range Contraction 0.00%
NR7 Range Contraction 0.00%
NR7-2 Range Contraction 0.00%
Narrow Range Bar Range Contraction -0.45%
NR7 Range Contraction -0.45%
Lower Bollinger Band Walk Weakness -0.45%
Inside Day Range Contraction -0.45%
Calm After Storm Range Contraction -1.46%
Lower Bollinger Band Walk Weakness -1.46%
Lower Bollinger Band Touch Weakness -1.46%

Older signals for SUPN ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Supernus Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing products for the treatment of central nervous system diseases. Its products include SPN-538, an extended release topiramate product that completed clinical trials in support of new drug application for the treatment of epilepsy; Epliga, an extended release oxcarbazepine, which is in Phase III clinical trials targeting epilepsy; SPN-810, a molindone hydrochloride that is in Phase II clinical trials for treatment for impulsive aggression in patients with attention deficit hyperactivity disorder; and SPN-812, a Phase II clinical trial product targeting attention deficit hyperactivity disorder. The company also develops SPN-809, which has an open investigational new drug application for the treatment of depression. It intends to market its products to specialty physicians, including neurologists and psychiatrists in the United States. The company was founded in 2005 and is based in Rockville, Maryland.
Health Pharmaceutical Pharmaceutical Industry Drug Discovery Clinical Trial Design Of Experiments Epilepsy Clinical Research Depression Attention Deficit Hyperactivity Disorder Clinical Trial Product Central Nervous System Diseases Neurology Treatment Of Central Nervous System Diseases Treatment Of Depression Treatment Of Epilepsy
Is SUPN a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 61.25
52 Week Low 30.05
Average Volume 589,759
200-Day Moving Average 40.9477
50-Day Moving Average 36.5632
20-Day Moving Average 35.7905
10-Day Moving Average 34.557
Average True Range 1.5944
ADX 33.41
+DI 11.0873
-DI 35.6655
Chandelier Exit (Long, 3 ATRs ) 33.9568
Chandelier Exit (Short, 3 ATRs ) 35.2832
Upper Bollinger Band 39.172
Lower Bollinger Band 32.409
Percent B (%b) 0.1
BandWidth 18.896076
MACD Line -1.0072
MACD Signal Line -0.6384
MACD Histogram -0.3688
Fundamentals Value
Market Cap 1.68 Billion
Num Shares 50.7 Million
EPS 1.98
Price-to-Earnings (P/E) Ratio 16.72
Price-to-Sales 8.00
Price-to-Book 8.81
PEG Ratio 1.42
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 34.20
Resistance 3 (R3) 34.20 33.85 34.01
Resistance 2 (R2) 33.85 33.57 33.84 33.95
Resistance 1 (R1) 33.47 33.40 33.66 33.47 33.89
Pivot Point 33.12 33.12 33.21 33.11 33.12
Support 1 (S1) 32.74 32.84 32.93 32.74 32.31
Support 2 (S2) 32.39 32.67 32.38 32.25
Support 3 (S3) 32.01 32.39 32.19
Support 4 (S4) 32.01